Week 7 Final Exam: NR546 NR-546

Week 7 Final Exam: NR546 / NR-546

(Latest 2025 / 2026) Advanced Pharmacology Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner | Study Questions and Answers | 100% Correct | Grade A - Chamberlain

Question:

Noradrenergic (NRI)

Answer:

atomoxetine (Strattera) -drug of choice for adults with ADHD -no abuse potential -tolerated well when prescribed in twice daily dosing-appropriate choice for comorbid substance abuse -may augment the effects of antidepressants and antianxiety medications -can be dosed at bedtime if fatigue is noted -unlikely to worsen tics

• / 4

Question:

Atomoextine indication

Answer:

ADHD ages 6 and up

Question:

Atomoextine action

Answer:

-Blocks norepinephrine reuptake pumps, may also increase dopamine in PFC

Question:

Atomoextine dosage

Answer:

-For children 70 kg or less: initial dose 0.5 mg/kg per day

-For adults and children over 70 kg: initial dose 40 mg/day

Question:

Atomoextine side effects

Answer:

-Sedation, fatigue , decreased appetite, priapism (rare), hypotension 2 / 4

Question:

Clonidine indications

Answer:

Hypertension ADHD 6-17years of age

Question:

Clonidine dose

Answer:

0.1 mg at HS

Question:

Clonidine action

Answer:

• enhances precortical function for better mental focus • appetite neutral • may help with sleep disturbances, administer at bedtime

• adverse effects: sedation, brain fog, dry mouth

• monitor of BP closely during initial titration • tapered to avoid rebound hypertension post discontinuation

• / 4

Question:

Guanfacine indication

Answer:

Hypertension, ADHD (6-17 years)

Question:

guanfacine dose

Answer:

1mg/day

Question:

Guanfacine action

Answer:

• may also be used for children with tics, sleep disturbances, or aggression • tolerability and convenience enhanced by once-daily oral controlled-release formulation

• adverse effects: sedation, headache, decreased appetite

• reduced side-effect profile comparable to clonidine • bedtime administration to avoid daytime sedation • central actions on postsynaptic alpha 2A receptors in the prefrontal cortex

• / 4